N-Desmethyltamoxifen

N-Desmethyltamoxifen

• CAS Number: 31750-48-8
• UNSPSC Description: N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].
• Target Antigen: Drug Metabolite; Endogenous Metabolite; Estrogen Receptor/ERR; PKC
• Type: Reference compound
• Related Pathways: Epigenetics;Metabolic Enzyme/Protease;TGF-beta/Smad;Vitamin D Related/Nuclear Receptor
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/n-desmethyltamoxifen.html
• Solubility: 10 mM in DMSO
• Smiles: CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCNC)C=C2)\C3=CC=CC=C3
• Molecular Weight: 357.50
• References & Citations: [1]Vertosick FT Jr, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol. 1994;19(2):97-103.|[2]Morad SA, et al. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics. Biochim Biophys Acta. 2015 Jul;1851(7):919-28.|[3]Reddel RR,et al. N-desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in vitro. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1179-81.|[4]Seong Hwan Kim,et al. Use of Antidepressants in Patients with Breast Cancer Taking Tamoxifen. J Breast Cancer. 2010 Dec;13(4):325-336.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported